Navigation

potassium phosphate/sodium acid phosphate (K-Phos M.F., K-Phos No. 2, K-Phos Neutral, Neutra-Phos, Uro-KP Neutral)

 

Classes: Electrolytes

Dosing and uses of K-Phos M.F., K-Phos No. 2 (potassium phosphate/sodium acid phosphate)

 

Adult dosage forms and strengths

potassium phosphate/sodium phosphate

tablet

  • 126mg/67mg
  • 250mg/298mg
  • 250mg/160mg

 

Hypophosphatemia

K-Phos Neutral: 1-2 tablets PO q4hr

Phos-NaK: 1 packet mixed with 75 mL water or juice

 

Low Urinary Phosphate

1-2 tablets PO q6hr

 

Dosing Modifications

Renal impairment: Use with caution in patients with chronic renal disease or renal function impairment

 

Administration

Take with full glass of water

Avoid antacids containing aluminum, magnesium, or calcium

May precipitate passage of existing kidney stones

 

Pediatric dosage forms and strengths

potassium phosphate/sodium phosphate

tablet

  • 126mg/67mg
  • 250mg/298mg
  • 250mg/160mg

 

Hypophosphatemia

<4 years: Safety and efficacy not established

>4 years: K-Phos Neutral, 1 tablet PO q6hr; Phos-NaK, 1 packet PO q6hr mixed with 75 mL water or juice

 

Low Urinary Phosphate

<4 years: Safety and efficacy not established

>4 years: 1-2 tablets PO q6hr

 

K-Phos M.F., K-Phos No. 2 (potassium phosphate/sodium acid phosphate) adverse (side) effects

Frequency not defined

Confusion

Dizziness

Gastrointestinal (GI) upset

Headache

Low urine output

Lower-extremity swelling

Mild laxative effect

Numbness or tingling

Shortness of breath

Tachycardia

Thirst

Weakness or heaviness of legs

Weight gain

 

Warnings

Contraindications

Patients with infected phosphate stones

Severe renal impairment

Hyperphosphatemia

Addison disease

Hyperkalemia

Infected urolithiasis

Struvite stone formation

 

Cautions

Cardiac disease, especially in digitalized patients

Adrenal insufficiency

Acute dehydration

Renal disease

Extensive tissue breakdown, as in severe burns

Myotonia congenita

Cirrhosis of liver

Edema

Hypertension

Hypoparathyroidism

Acute pancreatitis

Hepatic impairment

Hypernatremia

Metabolic alkalosis

 

Pregnancy and lactation

Pregnancy category: C

Lactation: Unknown whether drug is distributed in breast milk; caution is advised

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of K-Phos M.F., K-Phos No. 2 (potassium phosphate/sodium acid phosphate)

Mechanism of action

Acidifies urine; essential in physiologic processes

 

Elimination

Excretion: Kidney